This week on Pharm5:

  • CVS and Walgreens lift limits on at-home COVID-19 tests
  • Enjaymo (sutimlimab) approved for use in adults with cold agglutinin disease
  • The FDA’s draft guidance for development of non-opioid analgesics is open for public comments until April 11th, 2022
  • SURPASS-5 shows promising results for A1c lowering and weight loss at 40-weeks with tirzepatide
  • Mark Cuban’s CostPlus Drug Company has launched with limited formulary

References:

  1. Oshin O. CVs, Walgreens remove limits on at-home covid-19 tests. TheHill. https://thehill.com/policy/healthcare/public-global-health/593033-cvs-walgreens-remove-limits-on-at-home-covid-19-tests. Published February 6, 2022. Accessed February 10, 2022.
  2. Enjaymo [package insert]. U.S. Food and Drug Administration Website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761164s000lbl.pdf?utm_medium=email&utm_source=govdelivery. Revised February 2022.
  3. Cold agglutinin disease. NORD (National Organization for Rare Disorders). https://rarediseases.org/rare-diseases/cold-agglutinin-disease/#:~:text=Cold%20agglutinin%20disease%20(CAD)%20is,subtype%20of%20autoimmune%20hemolytic%20anemia. Published November 17, 2020. Accessed February 10, 2022.
  4. Commissioner of the FDA takes steps aimed at fostering development of non-addictive alternatives to opioids for acute pain management. U.S. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-takes-steps-aimed-fostering-development-non-addictive-alternatives-opioids-acute-pain-management?utm_campaign=&utm_content=1644424858&utm_medium=FDA%2CU.S.%2BFood%2Band%2BDrug%2BAdministration&utm_source=facebook%2Clinkedin. Accessed February 10, 2022.
  5. Center for Drug Evaluation and Research. Development of non-opioid analgesics for acute pain; draft guidance fo. U.S. Food and Drug Administration. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-non-opioid-analgesics-acute-pain-draft-guidance-industry. Accessed February 10, 2022.
  6. Dahl D, Onishi Y, Norwood P, et al. Effect of subcutaneous Tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes. JAMA. 2022;327(6):534. doi:10.1001/jama.2022.0078
  7. Costplusdrugs.com. https://costplusdrugs.com/. Accessed February 10, 2022.

Connect with us!

  • Listen to our podcast: Pharm5
  • Watch us on TikTok: @LizHearnPharmD
  • Follow us on Twitter: @LizHearnPharmD

See All 59 Episodes of "Pharm5"